CFSAN program priorities
This article was originally published in The Tan Sheet
Executive SummaryFDA center requests comments on fiscal 2003 program goals in June 21 Federal Register notice. Comments on ongoing broad program objective, new initiatives sought. Center asks which "B" list priorities from fiscal 2002 list should move to "A" status. Industry guidances on supplement regulation/labeling, "Food Security Action Plan," long-awaited supplements GMP reg were among "A" list priorities this year (1"The Tan Sheet" Feb. 4, 2002, p. 14). Ephedra strategy, transmissible spongiform encephalopathies goals were among "B" items. FDA seeks comments by Aug. 20...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.